February 2024
1. NAEEM AA, Abdulsamad SA, Zeng H, He G, et al
   FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells.
   Int J Oncol. 2024;64:18.
   

   >> Share

   
   
2. ZHONG K, Luo W, Li N, Tan X, et al
   CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3.
   Int J Oncol. 2024;64:20.
   

   >> Share

   
   January 2024
3. SUN X, Xin S, Zhang Y, Jin L, et al
   [Corrigendum] Long non?coding RNA CASC11 interacts with YBX1 to promote prostate cancer progression by suppressing the p53 pathway.
   Int J Oncol. 2024;64:5.
   

   >> Share

   
   November 2023
4. FENG K, Liu C, Wang W, Kong P, et al
   Emerging proteins involved in castration?resistant prostate cancer via the AR?dependent and AR?independent pathways (Review).
   Int J Oncol. 2023;63:127.
   

   >> Share

   
   June 2023
5. ZHANG Z, Wang W, Kong P, Feng K, et al
   New insights into lipid metabolism and prostate cancer (Review).
   Int J Oncol. 2023;62:74.
   

   >> Share

   
   March 2023
6. SHI SJ, Han DH, Zhang JL, Li Y, et al
   VIM‑AS1 promotes proliferation and drives enzalutamide resistance in prostate cancer via IGF2BP2‑mediated HMGCS1 mRNA stabilization.
   Int J Oncol. 2023;62:34.
   

   >> Share

   
   
7. MASUD N, Aldahish A, Iczkowski KA, Kale A, et al
   Zinc finger protein‑like 1 is a novel neuroendocrine biomarker for prostate cancer.
   Int J Oncol. 2023;62:38.
   

   >> Share

   
   February 2023
8. PAN D, Jia Z, Li W, Dou Z, et al
   [Corrigendum] The targeting of MTDH by miR‑145‑5p or miR‑145‑3p is associated with prognosis and regulates the growth and metastasis of prostate cancer cells.
   Int J Oncol. 2023;62:29.
   

   >> Share

   
   January 2023
9. CHEN B, Liu C, Long H, Bai G, et al
   N(6)‑methyladenosine‑induced long non‑coding RNA PVT1 regulates the miR‑27b‑3p/BLM axis to promote prostate cancer progression.
   Int J Oncol. 2023;62:16.
   

   >> Share

   
   September 2022
10. SUN X, Xin S, Zhang Y, Jin L, et al
    Long noncoding RNA CASC11 interacts with YBX1 to promote prostate cancer progression by suppressing the p53 pathway.
    Int J Oncol. 2022;61.
    

    >> Share

    
    June 2022
11. GOULIELMAKI M, Davanos N, Kogionou P, Batsaki P, et al
    The impact of radiation therapy on the TCR Vbeta chain repertoire in patients with prostate cancer.
    Int J Oncol. 2022;60.
    

    >> Share

    
    May 2022
12. CAO J, Chan WC, Chow MSS
    Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review).
    Int J Oncol. 2022;60.
    

    >> Share

    
    April 2022
13. HE Z, Gao Y, Li T, Yu C, et al
    HepaCAMPIK3CA axis regulates the reprogramming of glutamine metabolism to inhibit prostate cancer cell proliferation.
    Int J Oncol. 2022;60.
    

    >> Share

    
    December 2021
14. PAN XW, Gan SS, Ye JQ, Fan YH, et al
    [Corrigendum] SMC1A promotes growth and migration of prostate cancer in vitro and in vivo.
    Int J Oncol. 2021;59.
    

    >> Share

    
    July 2021
15. LU S, Dong Z
    Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptormediated signaling.
    Int J Oncol. 2021;59.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share